Partnerships countering the Covid-19 pandemic
We are proud to support our NHS and regional partners during the COVID-19 crisis.
We are proud to support our NHS and regional partners during the COVID-19 crisis.
Testing, research, PPE, personal support and more; the University of Birmingham community is responding to Covid-19 which has seen our existing partnerships work in new and vital ways.
Last updated: Tuesday 12 May 2020
From boosting laboratory testing capacity, coordinating clinical trials of new interventions to providing practical support to NHS workers; many of our academic clinicians are now working full time in the NHS fighting this disease. The Birmingham Health Partners alliance between the University of Birmingham and Birmingham Women's & Children's and University Hospitals has allowed us to adapt and work in partnership in new and vital ways.
Our researchers are collaborating to produce regular COVID-19 briefings based on the latest literature to support clinical colleagues and disseminate key information.
Here, we outline how the University of Birmingham is supporting NHS and regional partners. We'll keep this article updated with new developments as they occur so do check back in with us.
Support from University of Birmingham spinout companies
The Native Antigen Company was amongst the first commercial suppliers to produce antigens for SARS-CoV-2 (COVID-19), and is now collaborating with Oxgene™ to increase the production of antigens that will be used to develop diagnostics and vaccines. Further news from this spinout can be found online here and here. Follow @nativeantigen on Twitter for updates.
Alta Bioscience provides a peptide synthesising service – including peptide antigens for antibody generation – and this service remains fully staffed. The company is still able to meet the fast turnaround time for the majority of their customers. Follow @AltaBioscience on Twitter.
Abingdon Health is mobilising its rapid test development and manufacturing operations in order to scale-up the deployment of rapid diagnostics in response to the global COVID-19 outbreak and is recruiting for experienced scientists to join the York (UK) team. Follow @Abingdon_Health on Twitter.
The Native Antigen Company was amongst the first commercial suppliers to produce antigens for SARS-CoV-2 (COVID-19), and is now collaborating with Oxgene™ to increase the production of antigens that will be used to develop diagnostics and vaccines. Further news from this spinout can be found online here and here. Follow @nativeantigen on Twitter for updates.
Alta Bioscience provides a peptide synthesising service – including peptide antigens for antibody generation – and this service remains fully staffed. The company is still able to meet the fast turnaround time for the majority of their customers. Follow @AltaBioscience on Twitter.
Abingdon Health is mobilising its rapid test development and manufacturing operations in order to scale-up the deployment of rapid diagnostics in response to the global COVID-19 outbreak and is recruiting for experienced scientists to join the York (UK) team. Follow @Abingdon_Health on Twitter.
Read Covid-19 updates from across our Colleges:
Keep in touch
You can contact the Business Engagement team by email to businessteam@contacts.bham.ac.uk. On social media, follow us on Twitter and LinkedIn for regular updates and stories from our research and industry community.
The University's statement on Coronavirus (COVID-19) is updated regularly, in line with the latest advice from the Foreign and Commonwealth Office (FCO), World Health Organisation (WHO) and Public Health England (PHE). Our frequently asked questions (FAQs) are also updated regularly.
You can also find out more about our research relating to COVID-19.